Japanese Trade Distributors Stock News

TSE:6103
TSE:6103Machinery

Okuma (TSE:6103) Rallies On Strong Momentum While Fair Value Questions Linger

Okuma (TSE:6103) has recently drawn investor interest following a period of strong share price performance. The stock last closed at ¥5,010 after recording solid returns over the past year. See our latest analysis for Okuma. Recent trading has been strong for Okuma, with a 19.71% 1 month share price return and a 30.64% 3 month share price return contributing to a 39.84% 1 year total shareholder return. This suggests momentum has been building as investors reassess its prospects and risk...
TSE:4732
TSE:4732Specialty Retail

Is USS (TSE:4732) Undervalued On Stronger Used Vehicle Auction Demand?

USS (TSE:4732) is in focus after reporting year-on-year growth in consigned and contracted used vehicles, with its auction contract completion rate reaching 65.1% in the first quarter across key sites in Japan. See our latest analysis for USS. At a share price of ¥1,954.5, USS has posted a 30 day share price return of 6.60% and a year to date share price return of 14.00%, while its 5 year total shareholder return of 141.75% points to strong longer term compounding and suggests that momentum...
TSE:8113
TSE:8113Household Products

Does Unicharm’s India Pet Care Expansion Under Its Mid-Term Plan Change The Bull Case For Unicharm (TSE:8113)?

Unicharm Corporation has announced it will enter the Indian pet care market in July 2026, extending its pet care operations beyond Japan, North America, Asia and its recent move into Brazil. This expansion is part of Unicharm’s 13th Mid-Term Management Plan, which highlights pet care as a key growth driver in emerging markets such as India. We’ll now examine how Unicharm’s push into India’s pet care market under its new mid-term plan shapes the company’s investment narrative. Find 19...
TSE:2914
TSE:2914Tobacco

Japan Tobacco (TSE:2914) Gets A Zacks Upgrade As Fair Value Comes Back Into Focus

Japan Tobacco (TSE:2914) has drawn fresh attention after Zacks upgraded its rating, citing an upward trend in earnings estimates that points to improving expectations around the company’s underlying business performance and investor sentiment. See our latest analysis for Japan Tobacco. The recent Zacks upgrade comes alongside steady share price gains, with Japan Tobacco’s share price showing a 9.81% year to date return and a 5 year total shareholder return of 284.09%, suggesting momentum has...
TSE:7203
TSE:7203Auto

Toyota Stock Leads These Japanese Dividend Shares Worth A Closer Look

With inflation signals mixed and central banks treading carefully, many investors are looking more closely at income rather than just price swings. That is where Dividend Powerhouses with 3%+ yields come in. This screener focuses on companies paying more than a 5% dividend yield that is covered by profits, growing and historically stable, which can help you keep cash flowing even when growth data and bond yields are sending conflicting messages. In this article, you will see 3 of the...
TSE:4188
TSE:4188Chemicals

3 Japanese Stocks Tied To Rare Earth Supply Chain Shifts After China Export Curbs

China’s latest export controls on Japanese defense and technology companies have pushed supply chain security and rare earth independence back into the spotlight. For investors, this kind of shock can quickly reshape how risk and opportunity are priced across Japanese stocks exposed to the news. This article breaks down what the policy shift might mean for larger domestic supply chain players, and why some of them could see changing expectations around their role in Japan’s push for...
TSE:3050
TSE:3050Specialty Retail

Is DCM Holdings (TSE:3050) Undervalued As First Quarter Sales And Profit Rise?

DCM Holdings earnings event and what it means for investors DCM Holdings (TSE:3050) has drawn fresh attention after reporting first quarter results to May 31, 2026, with sales of ¥151,942 million and net income of ¥6,558 million, both higher than a year earlier. See our latest analysis for DCM Holdings. Despite the stronger first quarter figures, DCM Holdings’ recent share price performance has been mixed. The 1-day share price return was 1.01%, but the 90-day share price return declined...
TSE:9468
TSE:9468Media

Can Kadokawa (TSE:9468) Justify Its Valuation As Governance Pressure Builds?

Investor attention on Kadokawa (TSE:9468) has sharpened after Oasis Management, a significant shareholder, criticized the reappointment of CEO Takeshi Natsuno and highlighted the latest AGM vote as a key step in its accountability campaign. See our latest analysis for Kadokawa. Kadokawa’s recent governance headlines have arrived alongside a 7 day share price return of 7.72% and a 30 day share price return of 10.48%. Over the same period, the 1 year total shareholder return is slightly...
TSE:8630
TSE:8630Insurance

Sompo Holdings (TSE:8630) Completes Buyback Tranche, Is It Still 41% Overvalued?

Sompo Holdings (TSE:8630) is back in focus after the company reported progress on its open market share repurchase program, including completion of a ¥9.75b tranche. This has sharpened attention on its capital allocation plans. See our latest analysis for Sompo Holdings. The share buyback update comes after a strong run in Sompo Holdings' stock, with a 1 month share price return of 14.78% and a year to date share price return of 24.63%, alongside a 1 year total shareholder return of 65.55%...
TSE:9042
TSE:9042Transportation

Hankyu Hanshin Holdings (TSE:9042) Completes Buyback, Does The Valuation Still Look Fair?

Hankyu Hanshin Holdings (TSE:9042) has completed the repurchase of 4,868,700 shares, or 2.05% of outstanding stock, for ¥22,310.74 million, drawing fresh attention to its ongoing capital management approach. See our latest analysis for Hankyu Hanshin Holdings. Hankyu Hanshin Holdings’ recent buyback arrives after a mixed price pattern, with a 7.06% 7 day share price return and year to date share price return of 13.58%, while the 90 day share price return is down 5.31% and the 1 year total...
TSE:8233
TSE:8233Multiline Retail

Takashimaya Company (TSE:8233) Earnings Growth Puts Fair Value Back In Focus

What Takashimaya’s Latest Earnings Reveal Takashimaya Company (TSE:8233) reported first quarter sales of ¥96,187 million and net income of ¥11,082 million, compared with ¥90,824 million and ¥6,996 million a year earlier, putting its recent share performance into clearer context for investors. See our latest analysis for Takashimaya Company. Takashimaya’s latest results come after a strong run, with the share price up 36.31% year to date and the 1 year total shareholder return at 109.45%, even...
TSE:9948
TSE:9948Consumer Retailing

ARCS (TSE:9948) Keeps Guidance Steady, Is It Still Undervalued?

ARCS (TSE:9948) drew fresh attention after reporting first quarter results, with net sales up 2.7% year on year, operating profit up 5.9%, and profit attributable to owners rising 3.0%. See our latest analysis for ARCS. The first quarter update appears to have supported a stronger tone in ARCS shares recently, with a 1 month share price return of 9.15% and year to date gain of 4.45%. The 1 year total shareholder return of 18.71% and 5 year total shareholder return of 80.36% point to solid...
TSE:4516
TSE:4516Pharmaceuticals

The Bull Case For Nippon Shinyaku (TSE:4516) Could Change Following New Duchenne mRNA Option Deal - Learn Why

Nippon Shinyaku Co., Ltd. recently entered into an option agreement with Elixirgen Therapeutics to potentially secure exclusive worldwide rights to develop and commercialize EXG-7001, an investigational mRNA-based therapy for Duchenne muscular dystrophy that is currently in preclinical development ahead of planned U.S. trials. This move deepens Nippon Shinyaku’s rare-disease focus by targeting full-length dystrophin expression regardless of mutation type, potentially broadening the...
TSE:4568
TSE:4568Pharmaceuticals

Daiichi Sankyo (TSE:4568) Is Up 5.5% After EU Pan-Tumor Enhertu Approval And ADC Milestones

Daiichi Sankyo and AstraZeneca recently secured a European Commission approval for Enhertu across multiple HER2 positive metastatic solid tumors and received an EMA committee recommendation for Datroway as first-line treatment for certain triple-negative breast cancer patients, alongside board decisions on share-based compensation. These oncology milestones expand Daiichi Sankyo’s European treatment footprint, trigger a US$25 million milestone payment from AstraZeneca, and reinforce the...